[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339697-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339697-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unmutated-rras2-emerges-as-a-key-oncogene-in-post-partum-associated-triple-negative-breast-cancer","Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer","","Breast cancer remains difficult to treat, especially triple negative breast cancer (TNBC), which accounts for a substantial fraction of cases and shows resistance to existing therapies. Parity lowers lifetime breast cancer risk, yet pregnancy increases TNBC risk for years after childbirth, and no single universal driver gene has been identified. This study investigates RRAS2, a rarely mutated RAS-related GTPase, to determine whether dysregulated RRAS2 expression contributes to TNBC development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unmutated-rras2-emerges-as-a-key-oncogene-in-post-partum-associated-triple-negative-breast-cancer/339697/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unmutated-rras2-emerges-as-a-key-oncogene-in-post-partum-associated-triple-negative-breast-cancer/339697.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does RRAS2 play in triple negative breast cancer in this study?","Question",{"text":63,"@type":64},"The study shows that overexpression of wild-type RRAS2 is sufficient to drive TNBC development, and that higher RRAS2 expression without activating mutations is linked to a key driver role.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were RRAS2 effects tested in experimental models?",{"text":68,"@type":64},"Conditional knock-in mice were generated to overexpress wild-type human RRAS2 in mammary epithelial cells, assessing pregnancy-dependent TNBC development outcomes.",{"name":70,"@type":61,"acceptedAnswer":71},"What human genetic and molecular evidence supports an association with RRAS2?",{"text":72,"@type":64},"In human samples, RRAS2 is frequently overexpressed in tumors, its SNP rs8570 shows altered allele prevalence in tumor tissue, and RRAS2 gene amplification is observed in both tumors and blood.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339697,1790258258,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Cifuentes et al. Molecular Cancer (2024) 23:142 [https://doi.org/10.1186/s12943-024-02054-3](https://doi.org/10.1186/s12943-024-02054-3)  \nMolecular Cancer  \n RESEARCH Open Access  \nUnmutated RRAS2 emerges as a key   oncogene in post-partum-associated triple negative breast cancer  \nClaudia Cifuentes1, Clara L. Oeste 1,2, Isabel Fernández‑Pisonero3, Alejandro M. Hortal 1, Carmen García‑Macías3, Jeanne Hochart 1, Regina Rubira 1, Lydia Horndler 1, Carlos Horndler4, Xosé R. Bustelo3 and Balbino Alarcón1*  \nAbstract  \nBackground Breast cancer (BC) is the most common cancer in women, with triple negative BC (TNBC) accounting for 20% of cases. While early detection and targeted therapies have improved overall life expectancy, TNBC remains resistant to current treatments. Although parity reduces the lifetime risk of developing BC, pregnancy increases the risk of developing TNBC for years after childbirth. Although numerous gene mutations have been associated with BC, no single gene alteration has been identified as a universal driver. RRAS2 is a RAS‑related GTPase rarely found mutated in cancer.  \nMethods Conditional knock‑in mice were generated to overexpress wild type human RRAS2 in mammary epi‑ thelial cells. A human sample cohort was analyzed by RT‑qPCR to measure RRAS2 transcriptional expression  \nand to determine the frequency of both a single‑nucleotide polymorphism (SNP rs8570) in the 3’UTR region of RRAS2 and of genomic DNA amplification in tumoral and non‑tumoral human BC samples.  \nResults Here we show that overexpression of wild‑type RRAS2 in mice is sufficient to develop TNBC in 100% of females in a pregnancy‑dependent manner. In human BC, wild‑type RRAS2 is overexpressed in 68% of tumors across grade, location, and molecular type, surpassing the prevalence of any previously implicated alteration. Still, RRAS2 overexpression is notably higher and more frequent inTNBC and young parous patients. The increased preva‑ lence of the alternate C allele at the SNP position in tumor samples, along with frequent RRAS2 gene amplification in both tumors and blood of BC patients, suggests a cause‑and‑effect relationship between RRAS2 overexpression and breast cancer.  \nConclusions Higher than normal expression of RRAS2 not bearing activating mutations is a key driver in the majority of breast cancers, especially those of the triple‑negative type and those linked to pregnancy.  \nKeywords Breast cancer, TNBC, Parity, Driver gene, RRAS2, RAS proteins, SNP, Genetic marker  \n*Correspondence: Balbino Alarcón[balarcon@cbm.csic.es](balarcon@cbm.csic.es)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[http://creativecom](http://creativecom)‑ [mons.org/publicdomain/zero/1.0/](mons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to ","cbCaiqqElWDtogo6","https://ap.wps.com/l/cbCaiqqElWDtogo6","pdf",10441539,28,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background","[{\"question\":\"What role does RRAS2 play in triple negative breast cancer in this study?\",\"answer\":\"The study shows that overexpression of wild-type RRAS2 is sufficient to drive TNBC development, and that higher RRAS2 expression without activating mutations is linked to a key driver role.\"},{\"question\":\"How were RRAS2 effects tested in experimental models?\",\"answer\":\"Conditional knock-in mice were generated to overexpress wild-type human RRAS2 in mammary epithelial cells, assessing pregnancy-dependent TNBC development outcomes.\"},{\"question\":\"What human genetic and molecular evidence supports an association with RRAS2?\",\"answer\":\"In human samples, RRAS2 is frequently overexpressed in tumors, its SNP rs8570 shows altered allele prevalence in tumor tissue, and RRAS2 gene amplification is observed in both tumors and blood.\"}]","Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer | PDF",1790031670,71,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b625ca20a56e120cfe915ad05bf47cea.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e3e4909412ef46ab72c739707033596.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c80fc7198311201138b5a36ed76b80a6.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f292fe690bc07c7afe930a78589e4331.webp",980,1301]